Beijing Shunyi builds an international oral medicine innovation and transformation base
A new healthcare manufacturing/transformation base could add future capacity for oral medicine products.
Source →The trace
How it reaches your house.
Starting from Shandong Xinhua Pharmaceutical, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
North China Pharmaceutical (NCPC) →Prices rise6-Aminopenicillanic Acid (6-APA)
A new oral-medicine base should lift pull-through demand for NCPC's 25% share of 6-APA, and the low substitutability with a 24-month replacement horizon makes upward price pressure plausible.
62% confidenceNorth China Pharmaceutical (NCPC) →Prices riseMore oral-medicine capacity should raise demand for NCPC's 20% share of Pen G, and an 18-month replacement lead time suggests the market can tighten rather than adjust instantly.
60% confidenceNorth China Pharmaceutical (NCPC) →Prices rise7-Aminocephalosporanic Acid (7-ACA)
If the new base expands oral-medicine output, demand for NCPC's 18% share of 7-ACA should strengthen, and a 24-month replacement window limits quick substitution.
Hop 2
7-Aminocephalosporanic Acid (7-ACA) →Stands to benefitChina accounts for 75% of 7-ACA supply, so it would capture most of any incremental demand from the new base.
64% confidence7-Aminocephalosporanic Acid (7-ACA) →Stands to benefitNorth China Pharmaceutical (NCPC)
NCPC supplies 18% of 7-ACA, so extra oral-medicine capacity should help its output.
60% confidence7-Aminocephalosporanic Acid (7-ACA) →Stands to benefitCSPC Pharmaceutical Group Limited
CSPC supplies 22% of 7-ACA, so any downstream demand uplift should modestly benefit its sales.
Hop 3
Antibiotics →Prices rise7-Aminocephalosporanic Acid (7-ACA)
If the new oral-medicine base expands antibiotic output, this critical 7-ACA input should face tighter demand and higher prices because antibiotics production depends heavily on it.
54% confidence
Where it lands
What you buy, and what you own.
Goods you buy
Antibiotics
Companies you may own
North China Pharmaceutical (NCPC)CSPC Pharmaceutical Group LimitedCentrient Pharmaceuticals B.V.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.